This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (7)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

HAROLD O. PERRY, M.D.

Arch Dermatol. 1961;83(2):300-304.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Any discussion of the treatment of scleroderma should be prefaced with the remark that such treatment is most unsatisfactory under most circumstances. This general group of diseases is among the most difficult to treat and offers the greatest therapeutic challenge. The treatment of scleroderma has been characterized by an ever-changing spectrum of oral medication, injections, and surgical procedures.

The course of scleroderma is variable with periods of progression and remission despite supposedly definitive therapy. Except for the recent studies of Curtis and Jansen¹ regarding the prognosis of localized scleroderma, little information is available on the course of untreated scleroderma. The enthusiasm for the particular therapy rarely has been assessed against the prognosis of the nontreated patient. It is with this knowledge in mind that we must evaluate some therapy currently in use.

Although in the past each form of scleroderma was considered a separate entity, today the various clinical . . . [Full Text PDF of this Article]

Author Affiliations
ROCHESTER, MINN.

Mayo Clinic and Mayo Foundation (Dr. Perry, Section of Dermatology). The Mayo Foundation, Rochester, Minn., is a part of the Graduate School of the University of Minnesota.

Footnotes
Submitted for publication June 24, 1960.

Based on a paper that was read at the meeting of the American Academy of Dermatology, Chicago, Ill., December 5-10, 1959.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?